ArticleIntestinal research2026

The duration of prior anti-tumor necrosis factor agents is associated with the effectiveness of vedolizumab in patients with ulcerative colitis: a real-world multicenter retrospective study.

Taku Kobayashi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.